Precipitated and spontaneous withdrawal in baboons after chronic dosing with lorazepam and CGS 9896.
In order to assess the ability of lorazepam (20 mg/kg/day) and CGS 9896 (100 mg/kg/day) to produce physical-dependence in baboons, the occurrence of Ro 15-1788 precipitated withdrawal signs and spontaneous withdrawal signs were determined. Lorazepam-treated baboons displayed precipitated withdrawal signs following the administration of Ro 15-1788 (5 mg/kg), and displayed mild to moderate spontaneous withdrawal signs following termination of drug treatment. CGS 9896-treated baboons did not display Ro 15-1788 precipitated withdrawal signs and displayed either no or only mild spontaneous withdrawal signs.
D000818:Animals; D001570:Benzodiazepinones / Q000009:adverse effects; D005442:Flumazenil; D006801:Humans; D008140:Lorazepam / Q000009:adverse effects*; D008297:Male; D010215:Papio; D011720:Pyrazoles / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D019966:Substance-Related Disorders / Q000209:etiology
D001570:Benzodiazepinones; D011720:Pyrazoles; D005442:Flumazenil; C034704:2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3H)-one; D008140:Lorazepam